Phase III Randomized, Double-Blind, Placebo-Controlled Study of Dichlorphenamide for Periodic Paralyses and Associated Sodium Channel Disorders
Completed
Ohio State University
Phase 3
1992-06-01
OBJECTIVES:
I. Assess the efficacy of dichlorphenamide in the treatment of episodic weakness attacks in
patients with hyperkalemic periodic paralysis, paramyotonia congenita with periodic
paralysis, and hypokalemic periodic paralysis.
Phase III Randomized, Double-Blind, Placebo-Controlled Study of Dichlorphenamide for Periodic Paralyses and Associated Sodium Channel Disorders
Completed
National Center for Research Resources (NCRR)
Phase 3
1992-06-01
OBJECTIVES:
I. Assess the efficacy of dichlorphenamide in the treatment of episodic weakness attacks in
patients with hyperkalemic periodic paralysis, paramyotonia congenita with periodic
paralysis, and hypokalemic periodic paralysis.
National Institute of Neurological Disorders and Stroke (NINDS)
Phase 3
2007-06-01
The purpose of this study is to compare Dichlorphenamide with placebo (an inactive substance)
for prevention of episodes and for improvement of strength in hyperkalemic (HYP) and
hypokalemic (HOP) periodic paralysis. This study will also look at the long-term effects of
Dichlorphenamide in periodic paralysis.
The purpose of this study is to compare Dichlorphenamide with placebo (an inactive substance)
for prevention of episodes and for improvement of strength in hyperkalemic (HYP) and
hypokalemic (HOP) periodic paralysis. This study will also look at the long-term effects of
Dichlorphenamide in periodic paralysis.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
